The Potential Role of Serum Tissue Inhibitor of Metalloproteinase-2 (TIMP-2) as a Biomarker of Fibrosis in Patients With Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD). This evidence concerns the gene TIMP2 and fibrosis.